Molecular Imaging and Radionuclide Therapy最新文献

{"title":"Comparison of ⁶⁸Ga-FAPI-04 and ⁶⁸Ga-PSMA in a Case of Interstitial Lung Disease.","authors":"Hasan Önner, Abidin Kılınçer","doi":"10.4274/mirt.galenos.2024.93270","DOIUrl":"10.4274/mirt.galenos.2024.93270","url":null,"abstract":"<p><p>We present the ⁶⁸Ga-prostate-specific membrane antigen (PSMA) and ⁶⁸Ga-fibroblast activation protein inhibitor (FAPI)-04 positron emission tomography/computed tomography (PET/CT) findings comparatively of a 76-year-old man with a history of progressive dyspnea and evidence of interstitial lung disease (ILD) abnormalities on high-resolution CT. Moderate PSMA uptake was observed in areas with ILD abnormalities on ⁶⁸Ga-PSMA PET/CT. ⁶⁸Ga-FAPI-04 PET/CT showed relatively higher FAPI-04 uptake in these regions. These findings offer the potential to assess disease activity at the cellular and molecular levels. This approach may provide valuable insight into the pathophysiology of ILD beyond the structural changes captured by traditional imaging methods.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"129-131"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-PSMA-Avid Sinonasal Intestinal-Type Adenocarcinoma.","authors":"Hasan Önner, Halil Özer, Muhammet Fatih Gökmen, Orhan Önder Eren","doi":"10.4274/mirt.galenos.2024.48403","DOIUrl":"10.4274/mirt.galenos.2024.48403","url":null,"abstract":"<p><p>A rare tumor, intestinal-type adenocarcinoma (ITAC), accounts for 8-25% of all sinonasal malignancies. The tumor's histological resemblance to gastrointestinal tract adenocarcinoma is implied by its name. ITAC develops in the ethmoid sinus and upper nasal cavity. Herein, we present sinonasal ITAC with increased prostate-specific membrane antigen expression and fluorodeoxyglucose uptake.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"139-142"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidentally Detected High-Grade Follicular Derived Non-Anaplastic Thyroid Carcinoma on ⁶⁸Ga-PSMA PET-CT.","authors":"Parneet Singh, Srijani Mandal, Amit Kumar Adhya, Girish Kumar Parida, Kanhaiyalal Agrawal","doi":"10.4274/mirt.galenos.2025.46693","DOIUrl":"10.4274/mirt.galenos.2025.46693","url":null,"abstract":"<p><p>⁶⁸Ga--prostate-specific membrane antigen (PSMA)-11 positron emission tomography/computed tomography (PET/CT) is currently routinely used for the evaluation of prostate cancer. However, due to its whole-body imaging capability, it can incidentally identify pathologies beyond prostate cancer. Herein, we describe a case of a 67-year-old man who was recently diagnosed with prostate carcinoma (PCa). The patient had a high PSMA-avid thyroid carcinoma detected incidentally during the initial staging of PCa with ⁶⁸Ga-PSMA-11 PET-CT.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"159-161"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic Involvement in Follicular Lymphoma Detected on ¹⁸FDG-PET/CT.","authors":"Yassir Benameur, Salah Oueriagli Nabih, Omar Ait Sahel, Abderrahim Doudouh","doi":"10.4274/mirt.galenos.2024.87004","DOIUrl":"10.4274/mirt.galenos.2024.87004","url":null,"abstract":"<p><p>Follicular lymphoma (FL) is clinically classified as a common type of indolent non-Hodgkin's lymphoma. FL is generally indolent and has good prognosis, it can involve a variety of extranodal sites, including the gastrointestinal tract, bone marrow, spleen, liver, skin, and other organs. Secondary involvement of pancreas in FL is rare. We report the case of a patient with FL whose initial fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) revealed subdiaphragmatic involvement with isolated diffuse pancreatic hypermetabolism. Uncovering such rare site highlights the role of FDG-PET/CT in staging of lymphomas.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"132-134"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiological Distribution of ¹⁸F-FDG in the Spinal Cord of Disease-Free Subjects","authors":"Selin Kesim, Salih Özgüven","doi":"10.4274/mirt.galenos.2025.56514","DOIUrl":"10.4274/mirt.galenos.2025.56514","url":null,"abstract":"<p><strong>Objectives: </strong>¹⁸Fluorine-fluorodeoxyglucose (¹⁸F-FDG) uptake in the spinal cord is not unusual and may mimic metastatic disease. The physiological characterization and variability of spinal cord ¹⁸F-FDG metabolism provide valuable information, especially in patients with suspected malignancies. We aimed to investigate the physiological ¹⁸F-FDG uptake pattern within the spinal cord and its associations in a normal population.</p><p><strong>Methods: </strong>We retrospectively analyzed ¹⁸F-FDG positron emission tomography/computed tomography images of 140 adult patients who were confirmed to be disease-free over a one-year follow-up period. The maximal and mean standard uptake values (SUV_max, SUV_mean) were measured at each mid-vertebral level from C1 to L5, and normalized to liver and blood pool uptake. Correlations between ¹⁸F-FDG uptake and patient demographics, clinical parameters, and environmental temperature were evaluated.</p><p><strong>Results: </strong>¹⁸F-FDG uptake demonstrated a decreasing trend from the cervical to lumbar vertebrae, with a notable increase at the lower thoracic levels (T11-T12). There was a significant negative correlation between ¹⁸F-FDG uptake and age (p<0.001), fasting glucose level (p=0.016), and diabetic status (p=0.003). No significant association was found between spinal cord ¹⁸F-FDG uptake and gender, weight, height, body mass index, ¹⁸F-FDG dose, or environmental temperature.</p><p><strong>Conclusion: </strong>Normal distribution of ¹⁸F-FDG in the spinal cord of disease-free individuals decreases from cervical to lumbar levels, although it notably increases at the lower thoracic and mid-lower cervical levels. Uptake significantly decreases with age, with a higher fasting blood glucose level, and in diabetic patients.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":" ","pages":"107-113"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG PET/CT of a Multicentric Castleman Disease with Lymph Node and Skin Involvement.","authors":"Merve Yücel, Tarık Şengöz, Nilay Şen Türk","doi":"10.4274/mirt.galenos.2024.80388","DOIUrl":"10.4274/mirt.galenos.2024.80388","url":null,"abstract":"<p><p>Herein, we describe a rare case of multicentric Castleman disease with multiple lymph node and skin involvement. Ultrasonography of a 38-year-old patient with weakness and fever revealed multiple lymphadenopathies in both inguinal regions. Diagnosed via lymph node biopsy was Castleman's disease, a plasma cell variant. He was diagnosed with prurigo nodularis, lymphocytic vasculitis, and stasis dermatitis in the biopsies of skin lesions located in different regions. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography showed multiple hypermetabolic lymph nodes in the axilla, abdomen, pelvis, and both popliteal areas, multiple hypermetabolic skin thickenings, and skin lesions in both arms, legs, and feet.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"135-138"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-PENTIXAFOR PET/CT Captures Superscan in Refractory Multiple Myeloma.","authors":"Siven Kar, Harshita Gupta, Nusrat Shaikh, Vikram R Lele","doi":"10.4274/mirt.galenos.2025.94557","DOIUrl":"10.4274/mirt.galenos.2025.94557","url":null,"abstract":"<p><p>We present a case of a 40-year-old male with refractory multiple myeloma, assessed using ⁶⁸Gallium-PENTIXAFOR positron emission tomography/computed tomography (⁶⁸Ga-PENTIXAFOR PET/CT), revealing widespread and intense C-X-C motif chemokine receptor 4 (CXCR4) expression in multiple osteolytic lesions across axial and appendicular skeletons, including bone marrow deposits. Despite undergoing autologous hematopoietic stem cell transplantation and multiple lines of maintenance therapy, the patient experienced disease relapse and progression. The term \"superscan\" typically refers to diffuse skeletal uptake in conventional bone scans, primarily seen in advanced metastatic cancers or metabolic bone diseases. CXCR4, crucial for tumor growth and metastasis, binds C-X-C motif chemokine 12 (CXCL12) to promote cancer progression. PENTIXAFOR, a CXCR4-targeted PET agent, facilitates imaging of such malignancies. While superscans using PET/CT are rare, our case underscores the utility of ⁶⁸Ga-PENTIXAFOR PET/CT in evaluating CXCR4 expression in multiple myeloma, highlighting its potential as a diagnostic and prognostic tool in refractory disease management.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"162-164"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Integrin Imaging with [⁶⁸Ga]Ga-Trivehexin PET/CT for a Patient with Breast Cancer and Neuroendocrine Neoplasm: A Case of Both (¹⁸F)FDG PET/CT and [⁶⁸Ga]Ga-DOTATATE Positive but Integrin αvβ6 Negative Lesion on [⁶⁸Ga]Ga-Trivehexin PET.","authors":"Gamze Beydağı, Nalan Alan Selçuk, Kaan Akçay, Onur Yaprak, Murat Kalaycı, Levent Kabasakal","doi":"10.4274/mirt.galenos.2024.60320","DOIUrl":"10.4274/mirt.galenos.2024.60320","url":null,"abstract":"<p><p>Integrins play crucial roles in the migration of tumor cells during angiogenesis and metastasis. Consequently, αvβ6-integrin-targeted positron emission tomography (PET) radiopharmaceuticals have been developed and tested in humans, with clinical trials highlighting their applications in idiopathic pulmonary fibrosis and carcinomas. However, data on integrins are limited, and the role of [⁶⁸Ga]Ga-Trivehexin tomography/computed tomography (CT) PET/CT is not well-established. Some studies have suggested that [⁶⁸Ga]Ga-Trivehexin PET/CT is more specific than ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET/CT, which can yield false-positive results. It has been shown to be more efficient in evaluating pancreatic lesions and head and neck tumors. The role of [⁶⁸Ga]Ga Trivehexin PET/CT in neuroendocrine tumors is not yet clearly defined. In our case, integrin was negative in the pancreatic neuroendocrine tumor but positive in the breast lobular tumor. Additionally, we observed that the lobular carcinoma lesion in the right breast is somatostatin receptor+positive on [⁶⁸Ga]Ga-DOTATATE PET/CT.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"143-145"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Perspectives on Meningioma with Osseous Infiltration Revealed by ⁶⁸Ga-DOTA TOC PET-CT.","authors":"Sharjeel Usmani, Anjali Jain, Khulood Al Riyami, Syed Furqan Hashmi, Jamsari Khalid, Subhash Kheruka","doi":"10.4274/mirt.galenos.2024.99267","DOIUrl":"10.4274/mirt.galenos.2024.99267","url":null,"abstract":"<p><p>Meningiomas express the somatostatin receptor (SSTR). The utilization of SSTR ligands, specifically Gallium-68 (⁶⁸Ga) isotope, a radioactive isotope (⁶⁸Ga)-DOTA-labeled peptides, has demonstrated exceptional diagnostic precision for the detection of meningiomas, primarily due to the absence of normal brain and bone activity. We report a case of a 48-year-old woman with sphenoid wing meningioma who underwent ⁶⁸Ga-DOTA TOC positron emission tomography (PET) for tumor delineation. ⁶⁸Ga-DOTA TOC PET shows SSTR-avid meningioma in the right sphenoid/anterior temporal region with significant hyperostosis with high expression of SSTR in the bone. ⁶⁸Ga-DOTA TOC uptake in the hyperostosis signifies bone infiltration rather than reactive changes. ⁶⁸Ga-DOTA PET provides a better assessment of osseous involvement and provides additional information in terms of meningioma extent and planning for further management.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 2","pages":"152-155"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of ¹⁸F-FDG PET/CT and Related Parameters on Staging, Disease Management and Prognosis in Patients with Cholangiocarcinoma.","authors":"Fatih Tamer, Khayala Mammadli, Ülkem Yararbaş","doi":"10.4274/mirt.galenos.2025.62134","DOIUrl":"10.4274/mirt.galenos.2025.62134","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to evaluate the relationship of ¹⁸Fluorine-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) parameters with diagnostic efficacy, disease management and prognosis in patients with cholangiocarcinoma (CCA). The prognostic value of the spleen/liver ¹⁸F-FDG uptake ratio was also investigated.</p><p><strong>Methods: </strong>The clinical and imaging findings of 39 patients who met the diagnostic criteria and underwent ¹⁸F-FDG PET/CT imaging for staging between 2013 and 2023 were retrospectively analysed.</p><p><strong>Results: </strong>The tumour was intrahepatic in 34 patients and extrahepatic in 5 patients. PET/CT detected nodal involvement in 21 patients (53.8%) and distant metastases in 35 patients (89.7%). Fourteen cases (35.9%) had regional-distant metastases detected by PET/CT but not by magnetic resonance imaging/CT, and the stage of the disease changed accordingly. SUV_max, SUV_mean, metabolic tumor volume, tumour lesion glycolysis, tumor-to-liver ratio (tumour/liver parenchyma SUV_max), tumor-to-background ratio (tumour/blood pool SUV_max), tumor-stroma ratio (tumour/spleen parenchyma SUV_max), and standardized liver ratio (SLR) (spleen/liver SUV_max) did not differ based on tumour location. Recurrence occurred in 14 patients (35.9%), and 2 patients survived. When the cut-off values for the parameters were determined by the Youden index, progression-free survival (PFS) was significantly shorter in patients with an SLR value of less than 0.94 compared to the others (p=0.04). Nodal involvement, metastatic location, and other PET/CT parameters had no significant effect on PFS and overall survival.</p><p><strong>Conclusion: </strong>Our results highlight the efficacy of ¹⁸F-FDG PET/CT in staging nodal and distant metastases, similar to several studies in patients with CCA. Although SLR was found to have significant efficacy in PFS among the parameters we analysed, it is appropriate to evaluate the prognostic significance of these parameters in larger patient groups.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":" ","pages":"114-121"},"PeriodicalIF":0.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}